APA Zitierstil

McKay, F. C., Gatt, P. N., Fewings, N., Parnell, G. P., Schibeci, S. D., Basuki, M. A. I., . . . Booth, D. R. (2016). The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies. Clinical immunology (Orlando, Fla.), 163, 96. https://doi.org/10.1016/j.clim.2015.12.015

Chicago Zitierstil

McKay, Fiona C., et al. "The Low EOMES/TBX21 Molecular Phenotype in Multiple Sclerosis Reflects CD56+ Cell Dysregulation and Is Affected by Immunomodulatory Therapies." Clinical Immunology (Orlando, Fla.) 163 (2016): 96. https://dx.doi.org/10.1016/j.clim.2015.12.015.

MLA Zitierstil

McKay, Fiona C., et al. "The Low EOMES/TBX21 Molecular Phenotype in Multiple Sclerosis Reflects CD56+ Cell Dysregulation and Is Affected by Immunomodulatory Therapies." Clinical Immunology (Orlando, Fla.), vol. 163, 2016, p. 96.